Literature DB >> 7846031

T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors.

D M Hilbert1, M Y Shen, U R Rapp, S Rudikoff.   

Abstract

Major interest in the analysis of mature plasma cell neoplasias of mice and humans has focused on identification of precursor cells that give rise to mature malignant plasma cells. Although several laboratories have recently suggested that such cells are present in the granulomas of pristane-treated mice and the bone marrow of some multiple myeloma patients, the in vivo cellular interactions required for their differentiation into mature plasma cell tumors remains unclear. Given the extensive interactions of peripheral T cells and normal B cells, we assessed the potential role of T cells in plasma-cell tumor development, by using a myc, raf-containing retrovirus, J3V1, to induce plasmacytomas in normal BALB/c mice, T-cell-deficient nude mice, and T-cell-reconstituted nude mice. The B-lineage tumors arising in normal BALB/c mice were uniformly mature plasmacytomas, most of which secreted immunoglobulin. In contrast, nude mice yielded predominantly non-immunoglobulin-secreting B-cell lymphomas with a phenotype characteristic of peripheral B cells. T-cell reconstitution of nude mice prior to tumor induction resulted in a shift from B-cell lymphomas to plasmacytomas. These results imply that transformation can occur prior to terminal differentiation of B cells and that such transformed cells can be driven to terminal differentiation by peripheral T cells. These findings further suggest that, in human multiple myeloma, the ability of T cells to influence the differentiation state of transformed B cells may provide a mechanism by which malignant plasma cells found in the bone marrow could arise from clonotypically related less-mature B cells found in both the bone marrow and periphery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7846031      PMCID: PMC42677          DOI: 10.1073/pnas.92.3.649

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Induction of plasma-cell neoplasms and fibrosarcomas in BALB/c mice carrying diffusion chambers.

Authors:  R M MERWIN; G H ALGIRE
Journal:  Proc Soc Exp Biol Med       Date:  1959-07

2.  Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features.

Authors:  T M Grogan; B G Durie; C Lomen; C Spier; D P Wirt; R Nagle; G S Wilson; L Richter; E Vela; V Maxey
Journal:  Blood       Date:  1987-10       Impact factor: 22.113

3.  Evidence for the existence of circulating monoclonal B-lymphocytes in multiple myeloma patients.

Authors:  A Cassel; N Leibovitz; L Hornstein; M Quitt; E Aghai
Journal:  Exp Hematol       Date:  1990-12       Impact factor: 3.084

4.  Molecular cloning of the avian myelocytomatosis virus genome and recovery of infectious virus by transfection of chicken cells.

Authors:  B Vennström; C Moscovici; H M Goodman; J M Bishop
Journal:  J Virol       Date:  1981-08       Impact factor: 5.103

5.  Rapid induction of hemopoietic neoplasms in newborn mice by a raf(mil)/myc recombinant murine retrovirus.

Authors:  U R Rapp; J L Cleveland; T N Fredrickson; K L Holmes; H C Morse; H W Jansen; T Patschinsky; K Bister
Journal:  J Virol       Date:  1985-07       Impact factor: 5.103

6.  High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma.

Authors:  O F Ballester; L C Moscinski; G H Lyman; J V Chaney; H I Saba; A S Spiers; C Klein
Journal:  Blood       Date:  1994-04-01       Impact factor: 22.113

7.  Characterization of an inbred mouse exhibiting low responsiveness to phosphorylcholine. Antibodies from low-responder mice suggest gene conversion events within the S107VH gene family.

Authors:  D M Hilbert; M P Cancro
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

8.  Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells.

Authors:  G S Jensen; M J Mant; A J Belch; J R Berenson; B A Ruether; L M Pilarski
Journal:  Blood       Date:  1991-08-01       Impact factor: 22.113

9.  Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma.

Authors:  L Bergui; M Schena; G Gaidano; M Riva; F Caligaris-Cappio
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

10.  Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation.

Authors:  H Kubagawa; L B Vogler; J D Capra; M E Conrad; A R Lawton; M D Cooper
Journal:  J Exp Med       Date:  1979-10-01       Impact factor: 14.307

View more
  11 in total

1.  Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression.

Authors:  J J Letterio; A G Geiser; A B Kulkarni; H Dang; L Kong; T Nakabayashi; C L Mackall; R E Gress; A B Roberts
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

2.  Assessment of all-trans retinoic acid (ATRA) efficacy as a single agent in primary lymphoid neoplasia.

Authors:  N Swaminathan; G Lopez-Berestein; S Rudikoff
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

3.  Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma.

Authors:  P K Pattengale
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

4.  A Rare Case of Multple Myeloma (Mm) Presented With Pancytopaenia in A Patient of HIV - At Very Early Age.

Authors:  Sisir Kumar Patra; Manoj Soren; Anjan Kumar Das; Srishtidhar Mangal
Journal:  J Clin Diagn Res       Date:  2015-01-01

Review 5.  Differentiation and cancer: the conditional autonomy of phenotype.

Authors:  R G Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

6.  A case presenting with rapid renal damage caused by immunoglobulin D lambda-type multiple myeloma accompanied by granular lymphocyte proliferative disorder.

Authors:  Naro Ohashi; Kosuke Hirota; Akashi Togawa; Nobuharu Kosugi; Kunio Ohyama
Journal:  Clin Exp Nephrol       Date:  2011-03-03       Impact factor: 2.801

Review 7.  Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?

Authors:  Q Yi; A Osterborg
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

8.  Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.

Authors:  G Lattanzio; C Libert; M Aquilina; M Cappelletti; G Ciliberto; P Musiani; V Poli
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

9.  Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population.

Authors:  Lidia Karabon; Edyta Pawlak-Adamska; Anna Tomkiewicz; Anna Jedynak; Marek Kielbinski; Dariusz Woszczyk; Stanisław Potoczek; Anna Jonkisz; Kazimierz Kuliczkowski; Irena Frydecka
Journal:  Pathol Oncol Res       Date:  2011-07-09       Impact factor: 3.201

10.  Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Keren Osman; Matthew D Geller
Journal:  J Exp Med       Date:  2003-11-24       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.